Insights

GET STARTED

Experience Navion in action with a savings analysis!

Our custom Rx savings analysis delivers a side by-side assessment to ensure your groups have a single source of truth to choose the PBM option that’s right for them.

Already a Navion Partner?

Access co-branded resources and strategy tools via our Partner Portal.

Join our Newsletter

Stay up to date on features and releases.

By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.

Company

5500 Main Street,
Suite 220
Williamsville, NY 14221

(860) 352-5055
info@navionrx.com

Direct-to-Consumer (DTC) Prescription Drug Programs

Q1 2026 Drug Updates: New FDA Approvals, Generics, and Biosimilars to Watch

What Accurate PBM Modeling Really Takes — And Why Clients Deserve More Than a Dashboard

Department of Labor Proposes New PBM Fee Disclosure Requirements for Self-Insured Health Plans

The Audit That Pays for Itself: Why Reviewing Your PBM’s Performance Isn’t Optional

Q4 2025 Drug Landscape: New FDA Approvals, Label Changes, and Biosimilars

Making Sense of MAP, PAP, and CAP Programs

Filter Insights:

Latest Insights

Direct-to-Consumer (DTC) Prescription Drug Programs

Experience Navion in action with a savings analysis!

Insights

Direct-to-Consumer (DTC) Prescription Drug Programs

Q1 2026 Drug Updates: New FDA Approvals, Generics, and Biosimilars to Watch

What Accurate PBM Modeling Really Takes — And Why Clients Deserve More Than a Dashboard

Department of Labor Proposes New PBM Fee Disclosure Requirements for Self-Insured Health Plans

The Audit That Pays for Itself: Why Reviewing Your PBM’s Performance Isn’t Optional

Q4 2025 Drug Landscape: New FDA Approvals, Label Changes, and Biosimilars

Making Sense of MAP, PAP, and CAP Programs

Filter Insights:

Join our newsletter to stay up to date on market trends.

Latest Insights

Direct-to-Consumer (DTC) Prescription Drug Programs

Experience Navion in action with a savings analysis!